ENGLEWOOD, Colo. , Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024 . Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year. Q3 2024 net revenue of $50.
0 million . Q3 2024 net income of $2.4 million ; Diluted EPS $0.
07 . Q3 2024 cash flow from operations of $7.1 million .
Received FDA Clearance for new TensWave device. Management Commentary "In the third quarter of 2024 we continued our steady growth in orders as we positioned the company for long-term profitable growth," said Thomas Sandgaard , President and CEO of Zynex. "Positive cash flow remains strong and both revenue and earnings were within guidance for the third quarter.
"Our Pain Management division delivered a 13% improvement in orders year-over-year. We continue to see success evolving our pain management division to achieve our strategic goal of diversifying revenue streams through increased orders in orthopedic products. Revenue per sales rep increased 25% year-over-year to approximately $530,000 in the third quarter of 2024.
We are working to expedite the onboarding of new sales reps while maintaining a high standard for productivity. "Our focus on FDA approvals of next-generation devices and .